{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:58Z","timestamp":1792811578582,"version":"4.5.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Stiftung Tier\u00e4rztliche Hochschule Hannover (TIHO)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40263-021-00827-8","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T14:02:40Z","timestamp":1624024960000},"page":"935-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":352,"title":["The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-8973","authenticated-orcid":false,"given":"Wolfgang","family":"L\u00f6scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"827_CR1","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","volume":"4","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Vezzani A, O\u2019Brien TJ, Jette N, Scheffer IE, De Curtis M, Perucca P. Epilepsy. Nat Rev Dis Prim. 2018;4:18024.","journal-title":"Nat Rev Dis Prim."},{"key":"827_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Mosh\u00e9 SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512\u201321.","journal-title":"Epilepsia"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WCO.0000000000000803","volume":"33","author":"Z Chen","year":"2020","unstructured":"Chen Z, Brodie MJ, Kwan P. What has been the impact of new drug treatments on epilepsy? Curr Opin Neurol. 2020;33:185\u201390.","journal-title":"Curr Opin Neurol."},{"key":"827_CR4","first-page":"1048","volume":"35","author":"TR Browne","year":"1978","unstructured":"Browne TR. Drug therapy reviews: clinical pharmacology of antiepileptic drugs. Am J Hosp Pharm. 1978;35:1048\u201356.","journal-title":"Am J Hosp Pharm"},{"key":"827_CR5","unstructured":"Shorvon S, Perucca E, Engel JJ (2020) The treatment of epilepsy. Third edition. In: Shorvon S, Perucca E, Engel JJ (eds) (Oxford: Wiley-Blackwell)."},{"key":"827_CR6","doi-asserted-by":"crossref","unstructured":"Porter RJ, Dhir A, Macdonald RL, Rogawski MA (2012). Mechanisms of action of antiseizure drugs. In: Stefan H, Theodore WH, editors. Handbook of clinical neurology, vol. 108. Amsterdam: Elsevier. pp. 663\u2013681.","DOI":"10.1016\/B978-0-444-52899-5.00021-6"},{"key":"827_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314\u20139.","journal-title":"N Engl J Med."},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279\u201386.","journal-title":"JAMA Neurol."},{"key":"827_CR9","doi-asserted-by":"crossref","unstructured":"Janmohamed M, Brodie MJ, Kwan P. Pharmacoresistance\u2014epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020;168:107790.","DOI":"10.1016\/j.neuropharm.2019.107790"},{"key":"827_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","volume":"19","author":"E Perucca","year":"2020","unstructured":"Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19:544\u201356.","journal-title":"Lancet Neurol."},{"key":"827_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","volume":"52","author":"W L\u00f6scher","year":"2011","unstructured":"L\u00f6scher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia. 2011;52:657\u201378.","journal-title":"Epilepsia"},{"key":"827_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606\u201338.","journal-title":"Pharmacol. Rev."},{"key":"827_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.85.2213.525","volume":"85","author":"TJ Putnam","year":"1937","unstructured":"Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science. 1937;85:525\u20136.","journal-title":"Science"},{"key":"827_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00415-017-8391-5","volume":"264","author":"JM Keppel Hesselink","year":"2017","unstructured":"Keppel Hesselink JM, Kopsky DJ. Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. J Neurol. 2017;264:1617\u201321.","journal-title":"J Neurol."},{"key":"827_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","volume":"42","author":"W L\u00f6scher","year":"2017","unstructured":"L\u00f6scher W. Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res. 2017;42:1873\u201388.","journal-title":"Neurochem Res."},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0920-1211(94)90012-4","volume":"17","author":"W L\u00f6scher","year":"1994","unstructured":"L\u00f6scher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 1994;17:95\u2013134.","journal-title":"Epilepsy Res."},{"key":"827_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11064-017-2215-y","volume":"42","author":"RJ Porter","year":"2017","unstructured":"Porter RJ, Kupferberg HJ. The anticonvulsant screening program of the national institute of neurological disorders and stroke, NIH: history and contributions to clinical care in the twentieth century and beyond. Neurochem Res. 2017;42:1889\u201393.","journal-title":"Neurochem. Res."},{"key":"827_CR18","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1007\/s11064-017-2275-z","volume":"42","author":"JH Kehne","year":"2017","unstructured":"Kehne JH. National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42:1894\u2013903.","journal-title":"Neurochem Res."},{"key":"827_CR19","doi-asserted-by":"crossref","unstructured":"Wilcox KS, West PJ, Metcalf CS. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.","DOI":"10.1016\/j.neuropharm.2019.107811"},{"key":"827_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41582-019-0309-7","volume":"16","author":"JA French","year":"2020","unstructured":"French JA. Cenobamate for focal seizures - a game changer? Nat Rev Neurol. 2020;16:133\u20134.","journal-title":"Nat Rev Neurol."},{"issue":"Suppl. 15","key":"827_CR21","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1212\/WNL.94.15_supplement.1008","volume":"94","author":"P Klein","year":"2020","unstructured":"Klein P, Krauss GL, Aboumatar S, Kamin M. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Neurology. 2020;94(Suppl. 15):1008.","journal-title":"Neurology"},{"key":"827_CR22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1684\/epd.2019.1083","volume":"21","author":"E Perucca","year":"2019","unstructured":"Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord. 2019;21:319\u201329.","journal-title":"Epileptic Disord."},{"key":"827_CR23","doi-asserted-by":"crossref","unstructured":"Boada CM, French JA, Dumanis SB. Proceedings of the 15th antiepileptic drug and device trials meeting: state of the science. Epilepsy Behav. 2020;111:107189.","DOI":"10.1016\/j.yebeh.2020.107189"},{"key":"827_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm1074","volume":"10","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685\u201392.","journal-title":"Nat Med."},{"issue":"Suppl 7","key":"827_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(Suppl 7):26\u201333.","journal-title":"Epilepsia"},{"key":"827_CR26","first-page":"2629","volume":"44","author":"EA Swinyard","year":"1985","unstructured":"Swinyard EA, Kupferberg HJ. Antiepileptic drugs: detection, quantification, and evaluation. Fed Proc. 1985;44:2629\u201333.","journal-title":"Fed Proc."},{"key":"827_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","volume":"2","author":"W L\u00f6scher","year":"1988","unstructured":"L\u00f6scher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145\u201381.","journal-title":"Epilepsy Res."},{"key":"827_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrd2997","volume":"9","author":"M Bialer","year":"2010","unstructured":"Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9:68\u201382.","journal-title":"Nat Rev Drug Discov."},{"key":"827_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","volume":"126","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157\u201384.","journal-title":"Epilepsy Res."},{"key":"827_CR30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrd4126","volume":"12","author":"W L\u00f6scher","year":"2013","unstructured":"L\u00f6scher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757\u201376.","journal-title":"Nat Rev Drug Discov."},{"key":"827_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0013-4694(90)90099-6","volume":"76","author":"M Sato","year":"1990","unstructured":"Sato M, Racine RJ, McIntyre DC. Kindling: basic mechanisms and clinical validity. Electroenceph Clin Neurophysiol. 1990;76:459\u201372.","journal-title":"Electroenceph Clin Neurophysiol."},{"key":"827_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","volume":"232","author":"W L\u00f6scher","year":"1993","unstructured":"L\u00f6scher W, H\u00f6nack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147\u201358.","journal-title":"Eur J Pharmacol."},{"key":"827_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","volume":"30","author":"W L\u00f6scher","year":"2016","unstructured":"L\u00f6scher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30:1055\u201377.","journal-title":"CNS Drugs"},{"key":"827_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41582-018-0099-3","volume":"14","author":"ST Demarest","year":"2018","unstructured":"Demarest ST, Brooks-Kayal A. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies. Nat Rev Neurol. 2018;14:735\u201345.","journal-title":"Nat. Rev. Neurol."},{"key":"827_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0074-7742(02)49013-7","volume":"49","author":"KL Brunson","year":"2002","unstructured":"Brunson KL, Avishai-Eliner S, Baram TZ. ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol. 2002;49:185\u201397.","journal-title":"Int Rev Neurobiol."},{"key":"827_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/dvdy.79","volume":"249","author":"W Niu","year":"2020","unstructured":"Niu W, Parent JM. Modeling genetic epilepsies in a dish. Dev Dyn. 2020;249:56\u201375.","journal-title":"Dev Dyn."},{"key":"827_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Mosh\u00e9 SL, Peltola J, Roulet PE, Scheffer IE, Zuberi SM. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522\u201330.","journal-title":"Epilepsia"},{"key":"827_CR38","doi-asserted-by":"crossref","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966.","DOI":"10.1016\/j.neuropharm.2020.107966"},{"issue":"Suppl 3","key":"827_CR39","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1111\/j.1528-1157.1998.tb05115.x","volume":"39","author":"SF Berkovic","year":"1998","unstructured":"Berkovic SF. Aggravation of generalized epilepsies. Epilepsia. 1998;39(Suppl 3):S11\u20134.","journal-title":"Epilepsia"},{"key":"827_CR40","doi-asserted-by":"crossref","unstructured":"Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016.","DOI":"10.1111\/epi.13340"},{"key":"827_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362:790\u20139.","journal-title":"N Engl J Med."},{"key":"827_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/WNF.0000000000000200","volume":"40","author":"JM Song","year":"2017","unstructured":"Song JM, Hahn J, Kim SH, Chang MJ. Efficacy of treatments for infantile spasms: a systematic review. Clin Neuropharmacol. 2017;40:63\u201384.","journal-title":"Clin Neuropharmacol."},{"key":"827_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pediatrneurol.2020.01.015","volume":"108","author":"R Riikonen","year":"2020","unstructured":"Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr Neurol. 2020;108:54\u201364.","journal-title":"Pediatr Neurol."},{"key":"827_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.seizure.2018.10.016","volume":"63","author":"A Verrotti","year":"2018","unstructured":"Verrotti A, Striano P, Iapadre G, Zagaroli L, Bonanni P, Coppola G, Elia M, Mecarelli O, Franzoni E, Liso P, Vigevano F, Curatolo P. The pharmacological management of Lennox\u2013Gastaut syndrome and critical literature review. Seizure. 2018;63:17\u201325.","journal-title":"Seizure."},{"key":"827_CR45","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153\u201363.","journal-title":"Lancet"},{"key":"827_CR46","doi-asserted-by":"crossref","unstructured":"Canevini MP, Kotulska-Jozwiak K, Curatolo P, La Briola F, Peron A, Slowinska M, Strzelecka J, Vignoli A, Jozwiak S. Current concepts on epilepsy management in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178:299\u2013308.","DOI":"10.1002\/ajmg.c.31652"},{"key":"827_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","volume":"107","author":"JW Wheless","year":"2020","unstructured":"Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol. 2020;107:28\u201340.","journal-title":"Pediatr Neurol."},{"issue":"Suppl 3","key":"827_CR48","first-page":"S39","volume":"60","author":"JH Cross","year":"2019","unstructured":"Cross JH, Caraballo RH, Nabbout R, Vigevano F, Guerrini R, Lagae L. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019;60(Suppl 3):S39\u201348.","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"827_CR49","first-page":"S2","volume":"60","author":"D Mei","year":"2019","unstructured":"Mei D, Cetica V, Marini C, Guerrini R. Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies. Epilepsia. 2019;60(Suppl 3):S2\u20137.","journal-title":"Epilepsia"},{"key":"827_CR50","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, Devinsky O, Cross JH, Guerrini R, Talwar D, Miller I, Farfel G, Galer BS, Gammaitoni A, Mistry A, Morrison G, Lock M, Agarwal A, Lai WW, Ceulemans B. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243\u201354.","journal-title":"Lancet"},{"key":"827_CR51","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77:300\u20138.","journal-title":"JAMA Neurol."},{"key":"827_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s11096-018-0641-9","volume":"40","author":"MSA Campos","year":"2018","unstructured":"Campos MSA, Ayres LR, Morelo MRS, Carizio FAM, Pereira LRL. Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm. 2018;40:589\u201398.","journal-title":"Int J Clin Pharm."},{"key":"827_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ane.13025","volume":"139","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139:33\u201341.","journal-title":"Acta Neurol Scand."},{"key":"827_CR54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/epi4.12239","volume":"3","author":"E Perucca","year":"2018","unstructured":"Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3:220\u201330.","journal-title":"Epilepsia Open"},{"key":"827_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","volume":"44","author":"A Golyala","year":"2017","unstructured":"Golyala A, Kwan P. Drug development for refractory epilepsy: the past 25 years and beyond. Seizure. 2017;44:147\u201356.","journal-title":"Seizure."},{"key":"827_CR56","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","volume":"52","author":"J Costa","year":"2011","unstructured":"Costa J, Fareleira F, Ascencao R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280\u201391.","journal-title":"Epilepsia"},{"key":"827_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-017-8621-x","volume":"265","author":"Q Hu","year":"2018","unstructured":"Hu Q, Zhang F, Teng W, Hao F, Zhang J, Yin M, Wang N. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. J Neurol. 2018;265:1\u201311.","journal-title":"J. Neurol."},{"key":"827_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eplepsyres.2012.06.005","volume":"103","author":"L Gao","year":"2013","unstructured":"Gao L, Xia L, Zhao FL, Li SC. Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res. 2013;103:31\u201344.","journal-title":"Epilepsy Res."},{"key":"827_CR59","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/j.1528-1167.2007.01136.x","volume":"48","author":"DM Gazzola","year":"2007","unstructured":"Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia. 2007;48:1303\u20137.","journal-title":"Epilepsia"},{"key":"827_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ane.13257","volume":"142","author":"JJ Halford","year":"2020","unstructured":"Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142:91\u2013107.","journal-title":"Acta Neurol Scand."},{"key":"827_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol."},{"key":"827_CR62","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","volume":"61","author":"M Guignet","year":"2020","unstructured":"Guignet M, Campbell A, White HS. Cenobamate (XCOPRI\u00ae): can preclinical and clinical evidence provide insight into its mechanism of action? Epilepsia. 2020;61:2329\u201339.","journal-title":"Epilepsia"},{"key":"827_CR63","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ncl.2009.06.007","volume":"27","author":"LJ Stephen","year":"2009","unstructured":"Stephen LJ, Brodie MJ. Selection of antiepileptic drugs in adults. Neurol Clin. 2009;27:967\u201392.","journal-title":"Neurol Clin."},{"key":"827_CR64","doi-asserted-by":"crossref","unstructured":"Boon P, Ferrao SS, Jansen AC, Lagae L, Legros B, Weckhuysen S. Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update. Acta Neurol Belg. 2021;121:241\u2013257.","DOI":"10.1007\/s13760-020-01488-y"},{"key":"827_CR65","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","volume":"47","author":"T Glauser","year":"2006","unstructured":"Glauser T, Ben Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094\u2013120.","journal-title":"Epilepsia"},{"key":"827_CR66","doi-asserted-by":"crossref","unstructured":"Glauser T, Ben Menachem E, Bourgeois B, Cnaan A, Guerreiro C, K\u00c3lvi\u00c3inen R, Mattson R, French JA, Perucca E, Tomson T. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551\u201363.","DOI":"10.1111\/epi.12074"},{"key":"827_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas PE, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91:74\u201381.","journal-title":"Neurology"},{"key":"827_CR68","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas PE, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91:82\u201390.","journal-title":"Neurology"},{"key":"827_CR69","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1684\/epd.2016.0836","volume":"18","author":"E Burakgazi","year":"2016","unstructured":"Burakgazi E, French JA. Treatment of epilepsy in adults. Epileptic Disord. 2016;18:228\u201339.","journal-title":"Epileptic Disord."},{"key":"827_CR70","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210\u20138.","journal-title":"Lancet Neurol."},{"key":"827_CR71","unstructured":"Wyllie E. Wyllie's treatment of epilepsy. In: Wyllie E, editor. Philadelphia: Wolters Kluwer; 2021."},{"key":"827_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","volume":"77","author":"J Vidaurre","year":"2017","unstructured":"Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23\u201336.","journal-title":"Pediatr. Neurol."},{"key":"827_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14740338.2017.1248399","volume":"16","author":"X Lu","year":"2017","unstructured":"Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017;16:77\u201387.","journal-title":"Expert Opin Drug Saf"},{"key":"827_CR74","doi-asserted-by":"crossref","unstructured":"Diemar SS, Sejling AS, Eiken P, Andersen NB, J\u00f6rgensen NR. An explorative literature review of the multifactorial causes of osteoporosis in epilepsy. Epilepsy Behav. 2019;100:106511.","DOI":"10.1016\/j.yebeh.2019.106511"},{"key":"827_CR75","doi-asserted-by":"crossref","unstructured":"Klein P, Herzog AG. Endocrine aspects of partial epilepsy. in the comprehensive management and treatment of epilepsy. In: Schachter SC, Schomer DL, editors. San Diego: Academic Press; 1997. pp. 207\u2013232.","DOI":"10.1016\/B978-012621355-3\/50013-X"},{"key":"827_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","volume":"21","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD. Current status of antiepileptic drugs as preventive migraine therapy. Curr Treat Opt Neurol. 2019;21:16.","journal-title":"Curr Treat Opt Neurol."},{"key":"827_CR77","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2174\/1381612826666200110101604","volume":"26","author":"KK Goh","year":"2020","unstructured":"Goh KK, Chang SC, Chen CH, Lu ML. Therapeutic strategies for treatment-resistant depression: state of the art and future perspectives. Curr Pharm Des. 2020;26:244\u201352.","journal-title":"Curr Pharm Des"},{"key":"827_CR78","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","volume":"12","author":"AM Kanner","year":"2016","unstructured":"Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12:106\u201316.","journal-title":"Nat Rev Neurol."},{"key":"827_CR79","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/NDT.S512","volume":"3","author":"E Faught","year":"2007","unstructured":"Faught E. Topiramate in the treatment of partial and generalized epilepsy. Neuropsychiatr Dis Treat. 2007;3:811\u201321.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"827_CR80","doi-asserted-by":"crossref","unstructured":"Shvarts V, Chung S. Epilepsy, antiseizure therapy, and sleep cycle parameters. Epilepsy Res Treat. 2013;2013:670682.","DOI":"10.1155\/2013\/670682"},{"key":"827_CR81","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1210\/jc.2004-2376","volume":"90","author":"A Vinik","year":"2005","unstructured":"Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"827_CR82","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","volume":"179","author":"CW Goodman","year":"2019","unstructured":"Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695\u2013701.","journal-title":"JAMA Intern. Med."},{"key":"827_CR83","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMra1914484","volume":"383","author":"G Cruccu","year":"2020","unstructured":"Cruccu G, Di Stefano G, Truini A. Trigeminal neuralgia. N Engl J Med. 2020;383:754\u201362.","journal-title":"N Engl J Med."},{"key":"827_CR84","doi-asserted-by":"publisher","first-page":"6541798","DOI":"10.1155\/2020\/6541798","volume":"2020","author":"R Tzadok","year":"2020","unstructured":"Tzadok R, Ablin JN. Current and emerging pharmacotherapy for fibromyalgia. Pain Res Manag. 2020;2020:6541798.","journal-title":"Pain Res Manag."},{"key":"827_CR85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jsmc.2020.02.013","volume":"15","author":"GV Anguelova","year":"2020","unstructured":"Anguelova GV, Vlak MHM, Kurvers AGY, Rijsman RM. Pharmacologic and nonpharmacologic treatment of restless legs syndrome. Sleep Med Clin. 2020;15:277\u201388.","journal-title":"Sleep Med Clin."},{"key":"827_CR86","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ncl.2020.01.002","volume":"38","author":"WG Ondo","year":"2020","unstructured":"Ondo WG. Current and emerging treatments of essential tremor. Neurol Clin. 2020;38:309\u201323.","journal-title":"Neurol Clin."},{"key":"827_CR87","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1111\/epi.16395","volume":"60","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, Thomas SV. Executive summary: management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy. Epilepsia. 2019;60:2343\u20135.","journal-title":"Epilepsia"},{"key":"827_CR88","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s11064-017-2262-4","volume":"42","author":"M Kellogg","year":"2017","unstructured":"Kellogg M, Meador KJ. Neurodevelopmental effects of antiepileptic drugs. Neurochem Res. 2017;42:2065\u201370.","journal-title":"Neurochem Res."},{"key":"827_CR89","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","volume":"395","author":"A Sen","year":"2020","unstructured":"Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395:735\u201348.","journal-title":"Lancet"},{"key":"827_CR90","unstructured":"Anderson G. Pharmacokinetics and drug interactions. In: Wyllie's treatment of epilepsy. In: Wyllie E, editor. Philadelphia: Wolters and Kluwer; 2021. pp. 520\u2013531."},{"key":"827_CR91","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/epi.12234","volume":"54","author":"AK Srivastava","year":"2013","unstructured":"Srivastava AK, Alex AB, Wilcox KS, White HS. Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy. Epilepsia. 2013;54:1186\u201394.","journal-title":"Epilepsia"},{"key":"827_CR92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0920-1211(93)90058-F","volume":"15","author":"W L\u00f6scher","year":"1993","unstructured":"L\u00f6scher W, Rundfeldt C, H\u00f6nack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 1993;15:207\u201319.","journal-title":"Epilepsy Res."},{"key":"827_CR93","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","volume":"66","author":"P Kwan","year":"2006","unstructured":"Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006;66:1817\u201329.","journal-title":"Drugs"},{"key":"827_CR94","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","volume":"20","author":"MJ Brodie","year":"2011","unstructured":"Brodie MJ, Sills GJ. Combining antiepileptic drugs\u2014rational polytherapy? Seizure. 2011;20:369\u201375.","journal-title":"Seizure"},{"key":"827_CR95","doi-asserted-by":"crossref","unstructured":"Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice. Epilepsy Behav. 2020;104:106939.","DOI":"10.1016\/j.yebeh.2020.106939"},{"issue":"41","key":"827_CR96","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"2000","author":"CL Deckers","year":"2000","unstructured":"Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, van Rijn CM. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;2000(41):1364\u201374.","journal-title":"Epilepsia"},{"key":"827_CR97","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","volume":"26","author":"MJ Brodie","year":"1997","unstructured":"Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. 1997;26:423\u201332.","journal-title":"Epilepsy Res."},{"key":"827_CR98","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","volume":"40","author":"F Pisani","year":"1999","unstructured":"Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 1999;40:1141\u20136.","journal-title":"Epilepsia"},{"key":"827_CR99","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17512433.2018.1500895","volume":"11","author":"B Blaszczyk","year":"2018","unstructured":"Blaszczyk B, Miziak B, Czuczwar P, Wierzchowska-Cioch E, Pluta R, Czuczwar SJ. A viewpoint on rational and irrational fixed-drug combinations. Expert Rev Clin Pharmacol. 2018;11:761\u201371.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"827_CR100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1528-1157.1998.tb01268.x","volume":"39","author":"E Perucca","year":"1998","unstructured":"Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39:5\u201317.","journal-title":"Epilepsia"},{"key":"827_CR101","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1017\/S0012162206000843","volume":"48","author":"NA Gayatri","year":"2006","unstructured":"Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol. 2006;48:394\u20138.","journal-title":"Dev Med Child Neurol."},{"issue":"Suppl 8","key":"827_CR102","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1528-1167.2009.02233.x","volume":"50","author":"ER Somerville","year":"2009","unstructured":"Somerville ER. Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy). Epilepsia. 2009;50(Suppl 8):31\u20136.","journal-title":"Epilepsia"},{"key":"827_CR103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2005.03.001","volume":"33","author":"M Sazgar","year":"2005","unstructured":"Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005;33:227\u201334.","journal-title":"Pediatr. Neurol."},{"key":"827_CR104","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51:671\u20135.","journal-title":"Epilepsia"},{"key":"827_CR105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11940-018-0525-2","volume":"20","author":"N Gunawardane","year":"2018","unstructured":"Gunawardane N, Fields M. Acute symptomatic seizures and provoked seizures: to treat or not to treat? Curr Treat Opt Neurol. 2018;20:41.","journal-title":"Curr Treat Opt Neurol."},{"key":"827_CR106","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/WCO.0000000000000177","volume":"28","author":"SR Haut","year":"2015","unstructured":"Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28:143\u201350.","journal-title":"Curr Opin Neurol."},{"key":"827_CR107","doi-asserted-by":"crossref","unstructured":"Jafarpour S, Hirsch LJ, Ga\u00c3\u00adnza-Lein M, Kellinghaus C, Detyniecki K. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9\u201315.","DOI":"10.1016\/j.seizure.2018.05.013"},{"key":"827_CR108","doi-asserted-by":"crossref","unstructured":"Gidal B, Klein P, Hirsch LJ. Seizure clusters, rescue treatments, seizure action plans: Unmet needs and emerging formulations. Epilepsy Behav. 2020;112:107391.","DOI":"10.1016\/j.yebeh.2020.107391"},{"issue":"Suppl 1","key":"827_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1528-1167.2006.00658.x","volume":"47","author":"DH Lowenstein","year":"2006","unstructured":"Lowenstein DH. The management of refractory status epilepticus: an update. Epilepsia. 2006;47(Suppl 1):35\u201340.","journal-title":"Epilepsia"},{"key":"827_CR110","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48\u201361.","journal-title":"Epilepsy Curr."},{"key":"827_CR111","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381:2103\u201313.","journal-title":"N. Engl. J. Med."},{"key":"827_CR112","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","volume":"395","author":"JM Chamberlain","year":"2020","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395:1217\u201324.","journal-title":"Lancet"},{"key":"827_CR113","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1474-4422(11)70187-9","volume":"10","author":"AO Rossetti","year":"2011","unstructured":"Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922\u201330.","journal-title":"Lancet Neurol."},{"key":"827_CR114","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ana.21167","volume":"62","author":"FS Silverstein","year":"2007","unstructured":"Silverstein FS, Jensen FE. Neonatal seizures. Ann Neurol. 2007;62:112\u201320.","journal-title":"Ann Neurol."},{"key":"827_CR115","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40265-016-0554-7","volume":"76","author":"MD Donovan","year":"2016","unstructured":"Donovan MD, Griffin BT, Kharoshankaya L, Cryan JF, Boylan GB. Pharmacotherapy for neonatal seizures: current knowledge and future perspectives. Drugs. 2016;76:647\u201361.","journal-title":"Drugs"},{"key":"827_CR116","doi-asserted-by":"crossref","unstructured":"Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, Kuperman R, Harbert MJ, Michelson D, Joe P, Wang S, Rismanchi N, Le NM, Mower A, Kim J, Battin MR, Lane B, Honold J, Knodel E, Arnell K, Bridge R, Lee L, Ernstrom K, Raman R, Haas RH. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145.","DOI":"10.1542\/peds.2019-3182"},{"key":"827_CR117","doi-asserted-by":"crossref","unstructured":"Millar LJ, Shi L, Hoerder-Suabedissen A, Moln\u00c3\u00a1r Z. Neonatal hypoxia ischaemia: mechanisms, models, and therapeutic challenges. Front Cell Neurosci. 2017;11:78.","DOI":"10.3389\/fncel.2017.00078"},{"key":"827_CR118","first-page":"445","volume":"99","author":"DK Smith","year":"2019","unstructured":"Smith DK, Sadler KP, Benedum M. Febrile seizures: risks, evaluation, and prognosis. Am Fam Physician. 2019;99:445\u201350.","journal-title":"Am Fam Physician"},{"key":"827_CR119","first-page":"CD001905","volume":"1","author":"A McTague","year":"2018","unstructured":"McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2018;1:CD001905.","journal-title":"Cochrane Database Syst Rev"},{"key":"827_CR120","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.117.014399","volume":"70","author":"SRA Alles","year":"2018","unstructured":"Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev. 2018;70:315\u201347.","journal-title":"Pharmacol Rev."},{"key":"827_CR121","doi-asserted-by":"publisher","first-page":"595584","DOI":"10.3389\/fpsyt.2020.595584","volume":"11","author":"A Garakani","year":"2020","unstructured":"Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11:595584.","journal-title":"Front Psychiatry"},{"key":"827_CR122","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/NDT.S36453","volume":"9","author":"DS Baldwin","year":"2013","unstructured":"Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883\u201392.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"827_CR123","doi-asserted-by":"publisher","first-page":"574652","DOI":"10.3389\/fnins.2020.574652","volume":"14","author":"C Li","year":"2020","unstructured":"Li C, Xue L, Liu Y, Yang Z, Chi S, Xie A. Zonisamide for the treatment of Parkinson disease: a current update. Front Neurosci. 2020;14:574652.","journal-title":"Front Neurosci."},{"key":"827_CR124","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40263-020-00754-0","volume":"34","author":"P Gonzalez-Latapi","year":"2020","unstructured":"Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Non-dopaminergic treatments for motor control in Parkinson\u2019s disease: an update. CNS Drugs. 2020;34:1025\u201344.","journal-title":"CNS Drugs"},{"key":"827_CR125","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/jcpt.12179","volume":"39","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther. 2014;39:564\u20136.","journal-title":"J Clin Pharm Ther."},{"key":"827_CR126","doi-asserted-by":"crossref","unstructured":"Rogawski MA, L\u00f6scher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harb Perspect Med. 2016.","DOI":"10.1101\/cshperspect.a022780"},{"key":"827_CR127","doi-asserted-by":"publisher","first-page":"a022384","DOI":"10.1101\/cshperspect.a022384","volume":"6","author":"GP Brennan","year":"2016","unstructured":"Brennan GP, Baram TZ, Poolos NP. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in epilepsy. Cold Spring Harb Perspect Med. 2016;6:a022384.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"827_CR128","doi-asserted-by":"crossref","unstructured":"Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(Suppl.2):S90\u2013S105.","DOI":"10.1111\/epi.16539"},{"key":"827_CR129","doi-asserted-by":"publisher","first-page":"107702","DOI":"10.1016\/j.neuropharm.2019.107702","volume":"167","author":"GL Carvill","year":"2020","unstructured":"Carvill GL, Dulla CG, Lowenstein DH, Brooks-Kayal AR. The path from scientific discovery to cures for epilepsy. Neuropharmacology. 2020;167:107702.","journal-title":"Neuropharmacology"},{"key":"827_CR130","doi-asserted-by":"publisher","first-page":"107605","DOI":"10.1016\/j.neuropharm.2019.04.011","volume":"167","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W. The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments. Neuropharmacology. 2020;167:107605.","journal-title":"Neuropharmacology"},{"key":"827_CR131","doi-asserted-by":"crossref","unstructured":"Jozwiak S, Kotulska-Jozwiak K, Bebin M, Wong M. Modifying genetic epilepsies\u2014results from studies on tuberous sclerosis complex and their potential mpact. Neuropharmacology. 2020;166:107908.","DOI":"10.1016\/j.neuropharm.2019.107908"},{"key":"827_CR132","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11910-016-0708-8","volume":"16","author":"A Jeong","year":"2016","unstructured":"Jeong A, Wong M. mTOR inhibitors in children: current indications and future directions in neurology. Curr Neurol Neurosci Rep. 2016;16:102.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"827_CR133","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40272-019-00376-0","volume":"22","author":"CE van der Poest","year":"2020","unstructured":"van der Poest CE, Jansen FE, Braun KPJ, Peters JM. Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex. Paediatr Drugs. 2020;22:73\u201384.","journal-title":"Paediatr. Drugs"},{"key":"827_CR134","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/TCRM.S145630","volume":"15","author":"IE Overwater","year":"2019","unstructured":"Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY. Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag. 2019;15:951\u20135.","journal-title":"Ther Clin Risk Manag."},{"key":"827_CR135","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11910-012-0269-4","volume":"12","author":"DN Franz","year":"2012","unstructured":"Franz DN, Weiss BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 2012;12:294\u2013301.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"827_CR136","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.25956","volume":"89","author":"K Kotulska","year":"2021","unstructured":"Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, Feucht M, Krsek P, Nabbout R, Jansen AC, Wojdan K, Sijko K, Glowacka-Walas J, Borkowska J, Sadowski K, Domanska-Pakiela D, Moavero R, Hertzberg C, Hulshof H, Scholl T, Benova B, Aronica E, de Ridder J, Lagae L, Joszwiak S. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89:304\u201314.","journal-title":"Ann Neurol."},{"key":"827_CR137","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/ijms21020591","volume":"21","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W, Friedman A. Structural, molecular and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence or both? Int J Mol Sci. 2020;21:591.","journal-title":"Int J Mol Sci."},{"key":"827_CR138","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1528-1167.2007.01093.x","volume":"48","author":"W L\u00f6scher","year":"2007","unstructured":"L\u00f6scher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia. 2007;48:1245\u201358.","journal-title":"Epilepsia"},{"key":"827_CR139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm."},{"key":"827_CR140","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","volume":"47","author":"W L\u00f6scher","year":"2006","unstructured":"L\u00f6scher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253\u201384.","journal-title":"Epilepsia"},{"key":"827_CR141","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1600-0404.2005.00506.x","volume":"181","author":"E Perucca","year":"2005","unstructured":"Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl. 2005;181:30\u20135.","journal-title":"Acta Neurol Scand Suppl"},{"key":"827_CR142","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526\u201348.","journal-title":"Ther Drug Monit."},{"key":"827_CR143","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/epi.16542","volume":"61","author":"M Bialer","year":"2020","unstructured":"Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61:1082\u20139.","journal-title":"Epilepsia"},{"key":"827_CR144","doi-asserted-by":"crossref","unstructured":"Klein P, Tolbert D, Gidal BE. Drug\u2013drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy Behav. 2019;99:106459.","DOI":"10.1016\/j.yebeh.2019.106459"},{"key":"827_CR145","doi-asserted-by":"crossref","unstructured":"Sommerfeld-Klatta K, Zielinska-Psuja B, Karazniewcz-Lada, Glowka FK. New methods used in pharmacokinetics and therapeutic monitoring of the first and newer generations of antiepileptic drugs (AEDs). Molecules. 25;2020.","DOI":"10.3390\/molecules25215083"},{"key":"827_CR146","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239\u201376.","journal-title":"Epilepsia"},{"key":"827_CR147","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.yebeh.2011.11.025","volume":"23","author":"JA Cramer","year":"2012","unstructured":"Cramer JA. Tolerability of antiepileptic drugs: can we determine differences? Epilepsy Behav. 2012;23:187\u201392.","journal-title":"Epilepsy Behav."},{"key":"827_CR148","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-016-0406-8","volume":"31","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a clinician\u2019s overview. CNS Drugs. 2017;31:135\u201347.","journal-title":"CNS Drugs"},{"issue":"Suppl 8","key":"827_CR149","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/epi.12027","volume":"53","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012;53(Suppl 8):40\u20136.","journal-title":"Epilepsia"},{"key":"827_CR150","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","volume":"11","author":"T Tomson","year":"2012","unstructured":"Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803\u201313.","journal-title":"Lancet Neurol."},{"key":"827_CR151","first-page":"1146","volume":"257","author":"W L\u00f6scher","year":"1991","unstructured":"L\u00f6scher W, H\u00f6nack D. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptors. J Pharmacol Exp Ther. 1991;257:1146\u201353.","journal-title":"J Pharmacol Exp Ther."},{"key":"827_CR152","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0920-1211(02)00068-2","volume":"50","author":"H Klitgaard","year":"2002","unstructured":"Klitgaard H, Matagne A, Lamberty Y. Use of epileptic animals for adverse effect testing. Epilepsy Res. 2002;50:55\u201365.","journal-title":"Epilepsy Res."},{"key":"827_CR153","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0920-1211(02)00066-9","volume":"50","author":"B Meldrum","year":"2002","unstructured":"Meldrum B. Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res. 2002;50:33\u201340.","journal-title":"Epilepsy Res"},{"key":"827_CR154","volume-title":"Rational polypharmacy","author":"IE Leppik","year":"1996","unstructured":"Leppik IE. Rational polypharmacy. Amsterdam: Elsevier; 1996."},{"key":"827_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1157.1981.tb04327.x","volume":"22","author":"EH Reynolds","year":"1981","unstructured":"Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia. 1981;22:1\u201310.","journal-title":"Epilepsia"},{"key":"827_CR156","first-page":"121","volume-title":"The treatment of epilepsy","author":"E Perucca","year":"2009","unstructured":"Perucca E. General principles of medical management. In: Shorvon S, Perucca E, Engel JJ, editors. The treatment of epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009. p. 121\u201339.","edition":"3"},{"key":"827_CR157","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1017\/S0317167100034892","volume":"25","author":"A Guberman","year":"1998","unstructured":"Guberman A. Monotherapy or polytherapy for epilepsy? Can J Neurol Sci. 1998;25:S3\u20138.","journal-title":"Can J Neurol Sci."},{"key":"827_CR158","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1684\/epd.2016.0882","volume":"18","author":"D Schmidt","year":"2016","unstructured":"Schmidt D. Drug treatment strategies for epilepsy revisited: starting early or late? One drug or several drugs? Epileptic Disord. 2016;18:356\u201366.","journal-title":"Epileptic Disord."},{"key":"827_CR159","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","volume":"33","author":"P Skolnick","year":"2012","unstructured":"Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci. 2012;33:611\u201320.","journal-title":"Trends Pharmacol. Sci."},{"key":"827_CR160","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.eplepsyres.2016.02.003","volume":"122","author":"DG Kasteleijn-Nolst Trenit\u00e9","year":"2016","unstructured":"Kasteleijn-Nolst Trenit\u00e9 DG, Groenwold RH, Schmidt B, L\u00f6scher W. Single dose efficacy evaluation of two partial benzodiazepine receptor agonists in photosensitive epilepsy patients: a placebo-controlled pilot study. Epilepsy Res. 2016;122:30\u20136.","journal-title":"Epilepsy Res."},{"key":"827_CR161","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40263-013-0129-z","volume":"28","author":"C Rundfeldt","year":"2014","unstructured":"Rundfeldt C, L\u00f6scher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014;28:29\u201343.","journal-title":"CNS Drugs"},{"key":"827_CR162","doi-asserted-by":"crossref","unstructured":"Schidlitzki A, Bascunana P, Srivastava PK, Welzel L, Twele F, T\u00f6llner K, K\u00e4ufer C, Gericke B, Feleke R, Meier M, Polyak A, Ross TL, Gerhauser I, Bankstahl JP, Johnson MR, Bankstahl M, L\u00f6scher W. Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy. Neurobiol Dis. 2020;134:104664.","DOI":"10.1016\/j.nbd.2019.104664"},{"key":"827_CR163","doi-asserted-by":"crossref","unstructured":"Welzel L, Bergin D, Schidlitzki A, Twele F, Johne A, Klein P, L\u00f6scher W. Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Neurobiol Dis. 2021;149:105227.","DOI":"10.1016\/j.nbd.2020.105227"},{"key":"827_CR164","doi-asserted-by":"crossref","unstructured":"Boison D, Jarvis MF. Adenosine kinase: a key regulator of purinergic physiology. Biochem Pharmacol. 2020;114321.","DOI":"10.1016\/j.bcp.2020.114321"},{"key":"827_CR165","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/13543784.2020.1743678","volume":"29","author":"C Steriade","year":"2020","unstructured":"Steriade C, French J, Devinsky O. Epilepsy: key experimental therapeutics in early clinical development. Expert Opin Investig Drugs. 2020;29:373\u201383.","journal-title":"Expert Opin Investig Drugs"},{"key":"827_CR166","doi-asserted-by":"crossref","unstructured":"Klein P, Tyrlikova I. No prevention or cure of epilepsy as yet. Neuropharmacology. 2020;168:107762.","DOI":"10.1016\/j.neuropharm.2019.107762"},{"key":"827_CR167","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","volume":"8","author":"W L\u00f6scher","year":"2012","unstructured":"L\u00f6scher W, Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy? Nat Rev Neurol. 2012;8:661\u20132.","journal-title":"Nat Rev Neurol."},{"key":"827_CR168","volume-title":"Models of seizures and epilepsy","author":"A Pitk\u00e4nen","year":"2017","unstructured":"Pitk\u00e4nen A, Buckmaster PS, Galanopoulou AS, Mosh\u00e9 SL. Models of seizures and epilepsy. 2nd ed. London: Academic Press; 2017.","edition":"2"},{"key":"827_CR169","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-019-00666-8","volume":"33","author":"EC Wirrell","year":"2019","unstructured":"Wirrell EC, Nabbout R. Recent advances in the drug treatment of Dravet syndrome. CNS Drugs. 2019;33:867\u201381.","journal-title":"CNS Drugs"},{"key":"827_CR170","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553\u201364.","journal-title":"Nat Rev Neurosci"},{"key":"827_CR171","doi-asserted-by":"crossref","unstructured":"L\u00f6scher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? Epilepsia. 2021 (in press).","DOI":"10.1111\/epi.16832"},{"key":"827_CR172","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-94-017-8914-1_23","volume":"813","author":"SC Baraban","year":"2014","unstructured":"Baraban SC, L\u00f6scher W. What new modeling approaches will help us identify promising drug treatments? Adv Exp Med Biol. 2014;813:283\u201394.","journal-title":"Adv Exp Med Biol."},{"key":"827_CR173","doi-asserted-by":"crossref","unstructured":"Kaur H, Kumar B, Medhi B. Antiepileptic drugs in development pipeline: a recent update. eNeurologicalSci. 2016;4:42\u201351.","DOI":"10.1016\/j.ensci.2016.06.003"},{"key":"827_CR174","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 59;2018:1811\u201341.","DOI":"10.1111\/epi.14557"},{"key":"827_CR175","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.neurol.2020.01.364","volume":"176","author":"S Auvin","year":"2020","unstructured":"Auvin S. Lennox\u2013Gastaut syndrome: new treatments and treatments under investigation. Rev Neurol (Paris). 2020;176:444\u20137.","journal-title":"Rev Neurol (Paris)"},{"key":"827_CR176","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fifteenth eilat conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020;61:2340\u201364.","DOI":"10.1111\/epi.16725"},{"key":"827_CR177","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fifteenth eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61:2365\u201385.","DOI":"10.1111\/epi.16726"}],"updated-by":[{"DOI":"10.1007\/s40263-021-00853-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00827-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00827-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00827-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T23:58:23Z","timestamp":1725235103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00827-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":177,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00827-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"4 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-021-00853-6","URL":"https:\/\/doi.org\/10.1007\/s40263-021-00853-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access Publishing enabled and organized by Projekt DEAL. The open access publication was supported by the Deutsche Forschungsgemeinschaft and University of Veterinary Medicine Hannover, Foundation, within the funding program. No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WL and PK are co-founders as well as CFO and CSO, respectively, of PrevEp, Inc. (Bethesda, MD, USA). PrevEp did not fund this review and played no role in the writing of the review. WL was involved in the development of levetiracetam (UCB Pharma) and imepitoin (Elbion\/Boehringer Ingelheim); has received consultancy fees from Lundbeck, AC Immune, Clexio Biosciences, UCB Pharma, Pragma Therapeutics, Boehringer Ingelheim, Pfizer, and Johnson & Johnson; and has served on the advisory boards of Gr\u00fcnenthal, UCB Pharma, and Angelini Pharma. PK receives grant support from CURE\/US Department of Defense; has received consulting or speaker fees from or been on the advisory boards of Abbot, Aquestive, Arvelle, Eisai, Greenwich Pharmaceuticals, Neurelis, SK Life Science, Sunovion, and UCB Pharma; and is on the medical advisory board of Alliance-Stratus and the scientific advisory board of OB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"WL and PK performed the literature search and wrote the manuscript. Both authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}